Showing results (11-20 of 1,206) with videos related to

Sort By:
Pageof 121
Lancet (London, England)|March 13, 2019
Heart failure drug treatmentPatrick Rossignol, Adrian F Hernandez, Scott D Solomon, et al.
Hypertension (Dallas, Tex. : 1979)|July 11, 2012
Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIALPatrick Rossignol, Joelle Cridlig, Philippe Lehert, et al.
Family Practice|August 31, 2018
Health-related determinants of undiagnosed arterial hypertension: a population-based studyKénora Chau, Nicolas Girerd, Faiez Zannad, et al.
Clinical Cardiology|September 5, 2019
Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trialJoão Pedro Ferreira, Xavier Rossello, Bertram Pitt, et al.
Journal of Cardiac Failure|October 16, 2022
High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAALJoão Pedro Ferreira, Marvin Konstam, Patrick Rossignol, et al.
Journal of the American College of Cardiology|October 29, 2011
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudyPatrick Rossignol, Joël Ménard, Renaud Fay, et al.
European Heart Journal|April 11, 2025
Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney diseaseMasatake Kobayashi, Bertram Pitt, João Pedro Ferreira, et al.
JACC. Heart Failure|November 7, 2015
Prognostic Value of Estimated Plasma Volume in Heart FailureKévin Duarte, Jean-Marie Monnez, Eliane Albuisson, et al.
International Journal of Cardiology|September 19, 2018
Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failureDaniela Dobre, John Kjekshus, Patrick Rossignol, et al.
Clinical Cardiology|April 6, 2021
Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trialJoão Pedro Ferreira, John Gregson, Michael Böhm, et al.
Pageof 121